[
    [
        {
            "time": "2023-10-18",
            "original_text": "Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "phase 3a",
                    "obesity",
                    "oral semaglutide"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]